The Ibex Second ReadTM system analyzes cases in parallel with human pathologist review and identifies discrepancies between pathologist diagnoses and its own analysis. It subsequently alerts the users to discrepancies with a high clinical value and a high probability to enable a second human review, outlining suspicious areas and regions of interest. This enhances the quality control process in the lab and provides a safety net, resulting in decreased diagnostic error rates and more efficient workflow.
Ibex has deployed the first ever AI-based pathology cancer diagnosis system in a live clinical setting. The Ibex Second Read™ (SR) system was deployed in a large pathology institute to detect misdiagnosed prostate biopsies. All prostate cases are analyzed by the system and when a discrepancy with the diagnosis is detected, the case is sent back for an additional pathologist review.
- Ibex SR system deployed in March 2018
- Within the first week, reversed a misdiagnosis:
- 55-year-old male
- Original diagnosis: Benign prostatic hyperplasia (BPH)
- Ibex analysis: Malignant
- Direct impact on treatment: Diagnosis subsequently revised to adenocarcinoma with Gleason score 3+3
Portion of H&E image with algorithm results
(red = high probability for cancer)
Portion of confirmatory IHC (CK903) image
(unstained glands positive for adenocarcinoma)